IMMUNE TOLERANCE-INDUCING AGENT AND THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DISORDER
|Posted date||Jun 3, 2020|
|International application number||2019JP032352|
|International publication number||WO 2020045155|
|Date of international filing||Aug 20, 2019|
|Date of international publication||Mar 5, 2020|
|Title||IMMUNE TOLERANCE-INDUCING AGENT AND THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DISORDER|
|Abstract||(In Japanese)本発明は、アナフィラキシーを含む即時のアレルギー反応のリスクを抑制しながら、アレルギー疾患を治療または予防するアレルゲンワクチンを提供するという問題に取り組む。 本発明者らは、（1）アレルギー性疾患の被験者に特定の抗原（アレルゲン）とSF10を含む組成物を経口接種することにより、抗原感作による即時のアレルギー反応を抑制できることを見出した。 （2）アレルギー性疾患のない被験者に、特定の抗原（アレルゲン）とSF10を含む組成物を経口接種することにより、抗原に対する感作を抑制することができる。 これらの発見により、本発明が完成した。|
|Outline of related art and contending technology||
And allergies, and thus exposure to the causative agent (allergen) occurs, one disadvantage of the living body in an immune response. Heterologous human organisms as food digestion, absorption by the maintenance of life and therefore, no foreign matter cannot be digested with an incomplete state is constantly introduced into the body, such an incomplete biological defense reaction to the foreign substances (allergic reactions) so as not to, immune tolerance has been working normally. However, the birth of the infant in the current 5-10% of the population, 1 year old to the food allergy suffering from allergic diseases and some such as, in many of the natural healing of age 5-6 and, if not healed, atopic dermatitis, allergic diseases such as asthma (allergy march) with severe to be traveling. On the other hand, in the environment (pollen, mold, dust or the like of the house) allergen to, with the increase of age, it is immune to the failure state, may be developing allergy. Developed countries, the tendency of such allergies and is increasing every year following, some of the total population of about 30% is also referred to as suffering from allergic diseases and, a countermeasure has been strongly desired.
Conventional, effective treatment for the allergic disease is not present, and the purpose of reducing the treatment of allergy symptoms is generally used. In recent years, as the complete therapy of allergic diseases, allergen immunotherapy (also referred to as desensitization therapy) has been developed and attracted attention. Allergen immunotherapy is, under the control of the allergen (antigen) physician administered to the patient, in an attempt to induce immune tolerance and, with respect to food allergies (Patent Document 1 and 2) oral immunotherapy, mite allergic to pollen (Patent Document 3) immunotherapy sublingual, and transdermal immunotherapy known (Patent Document 4).
Allergen immunotherapy, immune therapy safely for allergen starting from a low dose, the dose gradually increased, at this time, the amount of administered allergen exceeds the threshold value can be immediately severe risk of allergy symptoms. Therefore, the allergen immunotherapy, standardized are used. is, processing the natural allergen (component extraction, heat treatment, chemical modifications, such as a sustained release formulation) by, which is capable of inducing immune tolerance while maintaining such allergens, immediate symptoms with reduced risk of inducing the present invention. as an example, the egg heat denaturing and powdered egg allergy or therapeutic composition (Patent Document 5 and 6), β - lactoglobulin modified therapeutic composition comprising a milk allergy (Patent Document 7) has been disclosed. In addition, Japanese cedar pollen allergen protein and the protein and the primary of the fusion protein Cryj1 Japanese cedar pollen Cryj2 used in the composition for the treatment (Patent Document 8), and the other Japanese cedar pollen allergen protein using the protein for treatment Japanese cedar pollen composition (Patent Document 9) has been disclosed.
However, even in the case of using such , desensitization therapy for severe allergies is difficult to completely prevent known (Non-Patent Document 1-3). Particularly, food allergies the patient for the infant or infant contained in an amount, desensitization therapy and the risk of further higher. In fact, in Japan, by oral immunotherapy, cardiopulmonary arrest (anaphylactic) severe allergic symptoms exhibited in some cases have been reported. From the above, a higher level of safety for oral immunotherapy (tolerance induction agent) of the development is in strong demand.
On the other hand, human alveolar type II cells secreted from 'pulmonary surfactant' is, the infant respiratory distress syndrome known as a silver bullet. The inventors of the present invention, 'pulmonary surfactant' as an adjuvant to early availability of interest, can be mass-produced artificial synthetic pulmonary surfactant (Synthetic pulmonary surfactant; SSF) was developed (Japanese Patent Laid-Open 10-12). Further, the inventors of the present invention, the thickener-vinyl (Carboxyvinyl polymer; CVP) by the addition, the transit time of the antigen by the SSF can be extended to locate, including the SSF and CVP and SF10 were developed or artificially synthesized mucosal adjuvants (Patent Document 13, Non-Patent Document 4, 5 and non-patent document).
The inventors of the present invention also relates to, influenza vaccine adjuvants for vaccination nasal as a result of the use SF10, Th1 and Th2 derived in a well-balanced immune system, as well as blood, bronchoalveolar lavage or nasal washing among influenza antigen specific IgA is increased, the, including inflammatory response does not occur any side effects to a clear (non-patent document 4, Non-Patent Document 5, Non-Patent Document 6). However, by the oral administration of SF10 does not attempt at all to this, the effect is completely unknown.
|Scope of claims||
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " IMMUNE TOLERANCE-INDUCING AGENT AND THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DISORDER "
- The University of Tokushima Department of Industry-Academia Collaboration Research Planning, Intellectual Property Office
- URL: https://www.tokushima-u.ac.jp/ccr/
- Address: 2-1, Minamijosanjima-cho, Tokushima-city, Tokushima , 770-8506
- Phone: 81-88-656-7592
- Fax: 81-88-656-7593